Pipeline

Fueled by a deep scientific expertise built over decades of research, Prothena is integrating scientific insights around protein dysregulation to advance a pipeline of therapeutic candidates for a number of neurodegenerative and rare peripheral amyloid diseases which affect millions of people and their families worldwide.

Program

Protein Target

Pre-clinical

Phase 1

Phase 2

Phase 3

Global Rights

PrasinezumabParkinson’s disease
(mAb)

α-Synuclein
(C-terminus)

Phase 3 PARAISO trial ongoing

Coramitug (PRX004)ATTR-CM
(mAb)

Transthyretin
(misTTR)

Phase 3 CLEOPATTRA trial ongoing

Moponetug (PRX005)Alzheimer’s disease
(mAb)

Tau (MTBR)

Phase 2 TargetTau-1 to complete in 1H 2027

PRX019Neurodegeneration
(mAb)

Undisclosed Target

Phase 1 completed

PRECLINICAL PORTFOLIO

TDP-43 CYTOPE^®ALS
(mAb-CYTOPE)

pTDP-43

PRX012-TfR³Alzheimer’s disease
(mAb-TfR)

Aβ (N-terminus)

CYTOPE^® R&D Collaborations⁴Ongoing with industry partners in multiple diseases & modalities

Undisclosed targets

CYTOPE^® Internal Targets⁴Multiple diseases and modalities

Undisclosed targets

mAb = Monoclonal Antibody; TfR = Transferrin Receptor; misTTR = misfolded transthyretin; ATTR-CM = transthyretin amyloid cardiomyopathy; MTBR = microtubule binding region; ALS = amyotrophic lateral sclerosis
¹ Orphan Drug Designation granted by FDA & EMA; ² FDA Fast Track designation; ³ PRX012 combination with TfR technology; ⁴ Various applications of CYTOPE^® technology.

Neurodegenerative

Rare Peripheral